The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele

Tekijä Johnsen, Jill M., Levy, Gallia G., Westrick, Randal J., Tucker, Priscilla K., Ginsburg, David
Julkaistu 2008

Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene

Tekijä Lemmerhirt, Heidi L., Shavit, Jordan A., Levy, Gallia G., Cole, Suzanne M., Long, Jeffrey C., Ginsburg, David
Julkaistu 2006

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A

Tekijä Yoneyama, Koichiro, Schmitt, Christophe, Kotani, Naoki, Levy, Gallia G., Kasai, Ryu, Iida, Satofumi, Shima, Midori, Kawanishi, Takehiko
Julkaisussa Clin Pharmacokinet (2017)

Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands

Tekijä Ellies, Lesley G., Ditto, David, Levy, Gallia G., Wahrenbrock, Mark, Ginsburg, David, Varki, Ajit, Le, Dzung T., Marth, Jamey D.
Julkaistu 2002

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Tekijä Schmitt, Christophe, Adamkewicz, Joanne I., Xu, Jin, Petry, Claire, Catalani, Olivier, Young, Guy, Negrier, Claude, Callaghan, Michael U., Levy, Gallia G.
Julkaisussa Thromb Haemost (2021)

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

Tekijä Lu, Genmin, Conley, Pamela B., Leeds, Janet M., Karbarz, Mark J., Levy, Gallia G., Mathur, Vandana S., Castillo, Janice, Crowther, Mark, Curnutte, John T.
Julkaisussa Blood Adv (2020)

Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS)

Tekijä Mahlangu, Johnny, Oldenburg, Johannes, Callaghan, Michael U., Shima, Midori, Mancuso, Maria Elisa, Trask, Peter, Recht, Michael, Garcia, Claudia, Yang, Renchi, Lehle, Michaela, Macharia, Harrison, Asikanius, Elina, Levy, Gallia G., Kruse‐Jarres, Rebecca, von Mackensen, Sylvia
Julkaisussa Haemophilia (2019)

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Tekijä Young, Guy, Liesner, Ri, Chang, Tiffany, Sidonio, Robert, Oldenburg, Johannes, Jiménez-Yuste, Victor, Mahlangu, Johnny, Kruse-Jarres, Rebecca, Wang, Michael, Uguen, Marianne, Doral, Michelle Y., Wright, Lilyan Y., Schmitt, Christophe, Levy, Gallia G., Shima, Midori, Mancuso, Maria Elisa
Julkaisussa Blood (2019)

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Tekijä Callaghan, Michael U., Negrier, Claude, Paz-Priel, Ido, Chang, Tiffany, Chebon, Sammy, Lehle, Michaela, Mahlangu, Johnny, Young, Guy, Kruse-Jarres, Rebecca, Mancuso, Maria Elisa, Niggli, Markus, Howard, Monet, Bienz, Nives Selak, Shima, Midori, Jiménez-Yuste, Victor, Schmitt, Christophe, Asikanius, Elina, Levy, Gallia G., Pipe, Steven W., Oldenburg, Johannes
Julkaisussa Blood (2021)